β-受体阻滞剂治疗心力衰竭对心功能及生存质量的影响
|
摘要
目的:探讨β-受体阻滞剂配伍治疗心衰患者的临床效果及对生存质量的影响。方法:将50例心衰患者根据治疗方案不同分为对照组(n=25)和观察组(n=25)。对照组采用利尿剂、洋地黄治疗;观察组配伍应用β-受体阻滞剂治疗,采用心力衰竭生活质量调查表(LHFQ)对患者生活质量进行评分,比较两组临床疗效及对生存质量的影响。结果:观察组治疗后左心室射血分数、心输出血量显著高于对照组(P<0.05);观察组治疗后心室舒张末期容积、左心室收缩末期容积水平显著低于对照组(P<0.05);观察组治疗后躯体功能、角色功能、认知功能、情绪功能、社会功能、整体功能评分高于对照组(P<0.05);两组治疗后药物不良反应发生率差异无统计学意义(P>0.05)。结论:心衰患者在利尿剂、洋地黄治疗基础上联合β-受体阻滞剂治疗效果理想。
Objective:To observe theβ-blockers combined with western medicine clinical effect and impact on quality of life in heart failure patients.Metholds:50cases of patients with heart failure within two wards cardiovascular diagnosis and treatment,according to the different treatment options divided into control group(n= 25)and observation group(n =25).The control group,diuretics,digitalis treatment,observation group jointβ-blocker therapy,the use of heart failure quality of life questionnaire(LHFQ)on quality of life score,the clinical efficacy of two groups were compared and the impact on quality of life.Results:After treatment,left ventricular ejection fraction,the amount of bleeding heart Shu,significantly higher than the control group(P<0.05);the observation group after treatment of ventricular end-diastolic volume,left ventricular end-systolic volume level was significantly lower than the control group(P <0.05);physical function,role function,cognitive function,emotional function,social function,the overall score was higher(P <0.05)were observed after treatment group;difference in the incidence of adverse drug reactions after treatment,the two groups was not statistically significance(P >0.05).Conclusion:In patients with heart failure diuretics,digitalis treatment based on the joint overβ-blocker treatment should be widely applied.
Objective:To observe theβ-blockers combined with western medicine clinical effect and impact on quality of life in heart failure patients.Metholds:50cases of patients with heart failure within two wards cardiovascular diagnosis and treatment,according to the different treatment options divided into control group(n= 25)and observation group(n =25).The control group,diuretics,digitalis treatment,observation group jointβ-blocker therapy,the use of heart failure quality of life questionnaire(LHFQ)on quality of life score,the clinical efficacy of two groups were compared and the impact on quality of life.Results:After treatment,left ventricular ejection fraction,the amount of bleeding heart Shu,significantly higher than the control group(P<0.05);the observation group after treatment of ventricular end-diastolic volume,left ventricular end-systolic volume level was significantly lower than the control group(P <0.05);physical function,role function,cognitive function,emotional function,social function,the overall score was higher(P <0.05)were observed after treatment group;difference in the incidence of adverse drug reactions after treatment,the two groups was not statistically significance(P >0.05).Conclusion:In patients with heart failure diuretics,digitalis treatment based on the joint overβ-blocker treatment should be widely applied.
引文
[1]华华,张景文.超短效β受体阻滞剂治疗严重冠状动脉病变患者心肌缺血的效果观察[J].中国当代医药,2013,20(26):90-91.
[2]周惠云,周启棣,甄胜西,等.两种β受体阻滞剂对心肌梗死患者心功能动态变化的影响[J].湖北科技学院学报:医学版,2013,27(3):193-196.
[3]唐阳峰,苏伟青,颜栋利,等.琥珀酸美托洛尔缓释片联合赖诺普利治疗慢性充血性心力衰竭的效果评价[J].海南医学,2014,25(13):1887-1889.
[4]黄昌宁.β-受体阻滞剂联合常规抗心衰药物治疗充血性心力衰竭的临床价值[J].医学理论与实践,2015,28(16):2164-2165.
[5]Dehina L,Vaillant F,Tabib A,et al.Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia[J].Naunyn Schmiedebergs Arch Pharmacol,2013,386(3):205-21
[6]王祥,邱彩玲.曲美他嗪治疗冠心病慢性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2012,20(2):270-271
[7]周艳芳.β-受体阻滞剂对慢性心力衰竭患者血清BNP、MMP-9水平和心功能的影响[J].中国民康医学,2014,26(13):95-96.
[8]姜婷,王魏魏,梅勇,等.β-受体阻滞剂联合西药治疗慢性心力衰竭疗效的Meta分析[J].临床心血管病杂志,2015,31(8):868-874.
[9]冯英,蒋玙姝,何倩雯,等.β-受体阻滞剂治疗舒张性心力衰竭的疗效及安全性的Meta分析[J].武汉大学学报:医学版,2015,36(6):992-999.
[10]马宁,边瓯.β-受体阻滞剂对心力衰竭老年患者血清中乳糖凝集素Galectin-3和可溶性基质裂解素sST2含量的影响[J].中国老年学杂志,2015,32(13):3746-3748.
[11]常成成,位庚,李红蓉,等.微血管内皮细胞损伤在心血管疾病发病中的作用及通络干预研究进展[J].时珍国医国药,2015,26(6):1459-1462.
[12]贺文婷.比索洛尔联合曲美他嗪治疗冠心病合并COPD心力衰竭患者的临床观察[J].陕西医学杂志,2015,44(12):1680-1681.
[13]安欣,孙媛媛,王归圣.温阳补心汤对慢性收缩性心力衰竭患者脑利钠肽水平影响的临床研究[J].陕西中医,2015,36(8):969-970.
[2]周惠云,周启棣,甄胜西,等.两种β受体阻滞剂对心肌梗死患者心功能动态变化的影响[J].湖北科技学院学报:医学版,2013,27(3):193-196.
[3]唐阳峰,苏伟青,颜栋利,等.琥珀酸美托洛尔缓释片联合赖诺普利治疗慢性充血性心力衰竭的效果评价[J].海南医学,2014,25(13):1887-1889.
[4]黄昌宁.β-受体阻滞剂联合常规抗心衰药物治疗充血性心力衰竭的临床价值[J].医学理论与实践,2015,28(16):2164-2165.
[5]Dehina L,Vaillant F,Tabib A,et al.Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia[J].Naunyn Schmiedebergs Arch Pharmacol,2013,386(3):205-21
[6]王祥,邱彩玲.曲美他嗪治疗冠心病慢性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2012,20(2):270-271
[7]周艳芳.β-受体阻滞剂对慢性心力衰竭患者血清BNP、MMP-9水平和心功能的影响[J].中国民康医学,2014,26(13):95-96.
[8]姜婷,王魏魏,梅勇,等.β-受体阻滞剂联合西药治疗慢性心力衰竭疗效的Meta分析[J].临床心血管病杂志,2015,31(8):868-874.
[9]冯英,蒋玙姝,何倩雯,等.β-受体阻滞剂治疗舒张性心力衰竭的疗效及安全性的Meta分析[J].武汉大学学报:医学版,2015,36(6):992-999.
[10]马宁,边瓯.β-受体阻滞剂对心力衰竭老年患者血清中乳糖凝集素Galectin-3和可溶性基质裂解素sST2含量的影响[J].中国老年学杂志,2015,32(13):3746-3748.
[11]常成成,位庚,李红蓉,等.微血管内皮细胞损伤在心血管疾病发病中的作用及通络干预研究进展[J].时珍国医国药,2015,26(6):1459-1462.
[12]贺文婷.比索洛尔联合曲美他嗪治疗冠心病合并COPD心力衰竭患者的临床观察[J].陕西医学杂志,2015,44(12):1680-1681.
[13]安欣,孙媛媛,王归圣.温阳补心汤对慢性收缩性心力衰竭患者脑利钠肽水平影响的临床研究[J].陕西中医,2015,36(8):969-970.